Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
19 September 2019Website:
http://www.exagen.comNext earnings report:
13 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Mon, 28 Oct 2024 20:00:12 GMTDividend
Analysts recommendations
Institutional Ownership
XGN Latest News
CARLSBAD, Calif., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of five abstracts at the 2024 American College of Rheumatology's (ACR) annual meeting, ACR Convergence 2024, being held November 14-19, 2024, at the Walter E. Washington Convention Center in Washington, D.C.
Exagen (XGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Exagen Inc. (XGN) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.28 per share a year ago.
CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August.
CARLSBAD, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended June 30, 2024, before the market opens on Monday, August 5, 2024. John Aballi, Exagen's President and Chief Executive Officer, and Kamal Adawi, Chief Financial Officer, will host a conference call to review the Company's results at 8:30 AM ET (5:30 AM PT).
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Exagen, Inc. (NASDAQ:XGN) Q1 2024 Earnings Conference Call will take place on May 13, 2024 at 8:30 AM ET. Present at the call will be Ryan Douglas, John Aballi, and Kamal Adawi. Participants include Mark Massaro, Kyle Mikson, and Dan Brennan. The operator will begin the call with greetings and instructions for participants to listen-only.
Exagen Inc. (XGN) reported a quarterly loss of $0.19 per share, which was better than the expected loss of $0.40 per share according to the Zacks Consensus Estimate. This is an improvement from the loss of $0.44 per share in the same quarter last year.
Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript
What type of business is Exagen?
Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
What sector is Exagen in?
Exagen is in the Healthcare sector
What industry is Exagen in?
Exagen is in the Diagnostics & Research industry
What country is Exagen from?
Exagen is headquartered in United States
When did Exagen go public?
Exagen initial public offering (IPO) was on 19 September 2019
What is Exagen website?
https://www.exagen.com
Is Exagen in the S&P 500?
No, Exagen is not included in the S&P 500 index
Is Exagen in the NASDAQ 100?
No, Exagen is not included in the NASDAQ 100 index
Is Exagen in the Dow Jones?
No, Exagen is not included in the Dow Jones index
When was Exagen the previous earnings report?
No data
When does Exagen earnings report?
The next expected earnings date for Exagen is 13 November 2024